APR-246 + Azacitidine
Phase 1/2UNKNOWN 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelodysplastic Syndrome With Gene Mutation
Conditions
Myelodysplastic Syndrome With Gene Mutation, Acute Myeloid Leukemia With Gene Mutations, Myeloproliferative Neoplasm, Chronic Myelomonocytic Leukemia
Trial Timeline
Sep 15, 2018 → May 15, 2021
NCT ID
NCT03588078About APR-246 + Azacitidine
APR-246 + Azacitidine is a phase 1/2 stage product being developed by Aprea Therapeutics for Myelodysplastic Syndrome With Gene Mutation. The current trial status is unknown. This product is registered under clinical trial identifier NCT03588078. Target conditions include Myelodysplastic Syndrome With Gene Mutation, Acute Myeloid Leukemia With Gene Mutations, Myeloproliferative Neoplasm.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03588078 | Phase 1/2 | UNKNOWN |
| NCT03072043 | Phase 1/2 | Completed |
Competing Products
20 competing products in Myelodysplastic Syndrome With Gene Mutation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 28 |
| JSP191 | Jasper Therapeutics | Phase 1 | 25 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 25 |
| GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II | GT Biopharma | Phase 1/2 | 33 |
| Erlotinib Hydrochloride | Astellas Pharma | Phase 2 | 52 |
| Decitabine + Decitabine + Decitabine | Eisai | Phase 2 | 52 |
| Decitabine + Valproic Acid | Eisai | Phase 2 | 52 |
| decitabine + decitabine | Eisai | Phase 2 | 52 |
| decitabine + azacitidine | Eisai | Approved | 85 |
| Decitabine | Eisai | Phase 2 | 52 |
| decitabine + decitabine + decitabine + decitabine | Eisai | Phase 1 | 33 |
| Decitabine, Arsenic Trioxide and Ascorbic Acid | Eisai | Phase 2 | 52 |
| Subcutaneous Decitabine | Eisai | Phase 1 | 33 |
| Decitabine | Eisai | Phase 2 | 52 |
| Galunisertib + Placebo | Eli Lilly | Phase 2/3 | 65 |
| DSP-7888 | Sumitomo Pharma | Phase 1/2 | 41 |
| TP-0184 | Sumitomo Pharma | Phase 1/2 | 41 |
| Decitabine | Johnson & Johnson | Phase 2 | 52 |
| Epoetin alfa | Johnson & Johnson | Phase 2 | 52 |
| ZARNESTRA, tipifarnib, R115777 | Johnson & Johnson | Phase 2 | 52 |
Other Products from Aprea Therapeutics
APR-246 + azacitidine + AzacitidinePhase 3
69
APR-246Phase 2
44
APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD)Phase 2
44
APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)Phase 1/2
33
APR-246 (eprenetapopt) + Acalabrutinib in CLL + APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL + APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT + APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RTPhase 1/2
33